Dr. Daniel Eidelberg Spratt on Risk Factors in Prostate Cancer

Video

​Daniel Eidelberg Spratt, MD, assistant professor, radiation oncology, University of Michigan Health System, discusses challenges regarding the classification of risk groups in prostate cancer.

Daniel Eidelberg Spratt, MD, assistant professor, radiation oncology, University of Michigan Health System, discusses challenges regarding the classification of risk groups in prostate cancer.

Many risk factors that are used to help determine treatment for prostate cancer are made up of relatively insensitive tests, says Spratt, including the rectal exam, PSA, or Gleason score.

These tests are not fully arcuate because they don’t provide any information regarding genetic risk factors. Oncologists must look at phenotypes, or the way all these features group together, to guide treatment, rather than actually genetically understanding how aggressive the tumors are or how responsive they may be to therapies.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD